Navigation Links
BioTrends Research Group is Recognized by the Philly 100 for the Second Consecutive Year
Date:9/8/2009

EXTON, Pa., Sept. 8 /PRNewswire/ -- For the second year in a row, BioTrends Research Group, Inc. has been ranked as one of the fastest-growing, privately-held companies in the Philadelphia region by the Philadelphia 100, a joint project of the Wharton Small Business Development Center, the Entrepreneurs' Forum of Greater Philadelphia, and the Philadelphia Business Journal.

Over the past five years, BioTrends has become an established player in the field of syndicated market research in the healthcare sector. "In spite of industry cut-backs, our business has flourished in the past two years. We believe this is due to our unique offering - high quality primary market research conducted in specialty pharmaceutical markets and shared across multiple clients which, in turn, provides a cost effective alternative to traditional single client proprietary projects," says Sharon Funk, Vice President of Market Research Services at BioTrends.

Originally focused entirely in Nephrology, BioTrends now offers syndicated reports in multiple specialties and therapeutic categories including Multiple Sclerosis, Rheumatoid Arthritis, Psoriasis, Gout/Hyperuricemia, Inflammatory Bowel Disease, and Lupus. The 2010 Publication Plan, published earlier this week, includes over 50 planned publications with new categories such as Fibromyalgia, Hepatitis, Macular Degeneration and Hypertension.

"We expect 2010 to be another exciting year for BioTrends as we expand into new therapeutic and new geographic areas. We are currently in the process of identifying savvy industry professionals to join the BioTrends team in 2010 to help us capitalize on the tremendous demand for our products and services" says Jennifer Robinson, Founder and President of BioTrends.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and cus
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Raptiva Withdrawal Offers Upside for Enbrel and Humira According to Latest BioTrends Survey of U.S. Dermatologists
2. Latest BioTrends Research Reports to Assess the Impact of the Withdrawal of Raptiva (efalizumab) on the Psoriasis Market
3. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
4. European Nephrologists Share Insights on the Management of Renal Anemia and Hyperphosphatemia in Latest BioTrends Report
5. BioTrends Releases TreatmentTrends(TM): Nephrology and Renal Dietitians, Two Syndicated Reports Providing Continuing Insight into the Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
6. BioTrends Research Group, Inc. Recognized as One of Philadelphias Fastest Growing Privately Held Companies
7. New Study by BioTrends Highlights Anemia Practice Patterns According to Anemia Managers in Both Dialysis Units and CKD Clinics/Offices
8. BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
9. New Study by BioTrends Highlights Practice Management Shifts Among European Nephrologists
10. BioTrends Releases Two Publications - TreatmentTrends(TM): Nephrologists and TreatmentTrends(TM): Renal Dietitians - Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
11. BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Santa Clara, California (PRWEB) March 03, 2015 ... and development service company, has launched a new Life ... research reagents for preclinical research. , The first ... monoclonal antibody isotype controls, and soon to be released ... The company will continue to expand their life science ...
(Date:3/3/2015)... ROCKVILLE, Md. , March 3, 2015  RegeneRx ... an editorial in the scientific journal, Expert Opinion ... and his colleague, Dr. Zhenggang Zhang , at ... reported that Thymosin beta 4 (TB4) has ... (PNS) remodeling 24 hours or more post-injury, leading to ...
(Date:3/3/2015)... March 03, 2015 Becht Engineering ... that it has acquired The CECON Group, Inc., ... transaction were not announced. , Becht Engineering ... energy sector including oil and gas production, refining, ... and nuclear power sectors. The company has twelve ...
(Date:3/3/2015)... , Mar. 03, 2015 Research and Markets ... addition of Jain PharmaBiotech,s new report "Gene ... their offering. , Gene therapy ... nonviral vectors and cell therapy with genetically modified ... drug delivery and various routes of administration as ...
Breaking Biology Technology:Crown Bioscience Launches Life Science Product Catalog 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3
... than a dozen internationally renowned speakers, including a key ... coming to New Haven, CT to present at StemCONN ... March 23-24, 2009.The roster includes scientists from UConn,s Stem ... new human embryonic stem cell lines that will be ...
... national physician group practice company, announced today that management is scheduled to present at the UBS 2009 Global Healthcare ... UBS 2009 Global Healthcare Services Conference, ... Adam Singer, M.D., Chairman and CEO, ... Jeff Taylor, President and COO, ...
... 2 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: ... company developing and commercializing products for the ... that it has entered into an agreement ... provide financial advisory services in connection with ...
Cached Biology Technology:Obama Advisor Joins Connecticut and International Scientists at New Haven Stem Cell Symposium 2IPC The Hospitalist Company, Inc. to Present at UBS 2009 Global Healthcare Services Conference 2Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value 2
(Date:2/5/2015)... Calif. , Jan. 30, 2015  It is ... great power and potential for genomic science as a ... in disease prevention and treatment.  I was honored to ... new, government-funded precision medicine program. Since ... the science of genomics—from the first sequenced genome of ...
(Date:1/22/2015)... /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry news, ... website design. "When we launched FindBiometrics 12 years ... O,Neill , founder and CEO of FindBiometrics. "Now it,s maturing ... the key players on a very broad scale.  We are ...
(Date:1/22/2015)... , Jan. 16, 2015  A man-made form of ... and other mental capabilities in adults with mild cognitive ... study led by researchers at Wake Forest Baptist Medical ... diagnosed with amnesic mild cognitive impairment (MCI) or mild ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... to learn more? You probably aren,t watching television then. ... Xiaoquan Zhao suggests that watching television has no significant ... change. Reading newspapers and using the web, however, seem ... The study, "Media Use and Global Warming Perceptions: A ...
... a grant of $8,950,590 provided through the American Recovery and ... Diego looking for the biological bases of differences in human ... collect a wealth of data about brain development in children. ... Institute on Drug Abuse (NIDA), a part of the National ...
... more than $29 million for the University of California, ... former gold mine in South Dakota into the world,s ... the National Science Board, is for a preliminary design ... a facility at the former Homestake gold mine in ...
Cached Biology News:Television has less effect on education about climate change than other forms of media 2Stimulus grant of nearly $9 million to UC San Diego funds big study of young brains 2Stimulus grant of nearly $9 million to UC San Diego funds big study of young brains 3NSF authorizes $29 million for preliminary design of world's deepest underground laboratory 2NSF authorizes $29 million for preliminary design of world's deepest underground laboratory 3
... Synergistic enzyme mix (Thermoprime Plus DNA ... At least four times higher fidelity than ... of standard Taq DNA polymerase, Amplifies DNA ... PCR, long PCR, PCR for cloning and ...
... Methylation-specific PCR (MSP) is a new ... gene methylation utilizing small amounts of ... initial bisulfite reaction to modify the ... specific primers designed to distinguish methylated ...
... m7G(5')ppp(5')G (Cap Analog) is used for the ... in vitro transcription reactions. Substitution of cap ... GTP in an in vitro transcription reaction ... structure into a large fraction of the ...
... HT is designed for extended ... HT is ideal for applications ... primer extension assays. iEMS Incubator/Shaker ... one-cabinet model, allowing the capacity ...
Biology Products: